Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines

Abstract

Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.

1 - 2 . (canceled) 
     
     
         3 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, YKL-40 peptide, and a GP100 peptide. 
     
     
         4 - 5 . (canceled) 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, the YKL-40 peptide comprises SEQ ID NO:10, and the GP100 peptide comprises SEQ ID NO:11. 
     
     
         7 - 24 . (canceled) 
     
     
         25 . A method of vaccinating a patient against glioma, wherein a composition comprising EphA2 883-891  is introduced into the patient under conditions sufficient for the patient to develop a CTL response. 
     
     
         26 . (canceled) 
     
     
         27 . The pharmaceutical composition of  claim 3 , wherein one or more of the peptides are loaded on dendritic cells. 
     
     
         28 - 29 . (canceled) 
     
     
         30 . The pharmaceutical composition of  claim 3 , further comprising an adjuvant. 
     
     
         31 . The pharmaceutical composition of  claim 30 , wherein the adjuvant is Montanide ISA-51. 
     
     
         32 - 38 . (canceled) 
     
     
         39 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of  claim 3 . 
     
     
         40 . The method of  claim 39 , further comprising administering to the subject a helper T cell epitope. 
     
     
         41 . The method of  claim 40 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140  core peptide. 
     
     
         42 . The method of  claim 39 , further comprising administering to the subject an immune response modifier. 
     
     
         43 . The method of  claim 42 , wherein the immune response modifier is poly-ICLC or imiquimod. 
     
     
         44 . The method of  claim 39 , wherein the subject is human. 
     
     
         45 . The method of  claim 39 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally. 
     
     
         46 . The method of  claim 39 , wherein the pharmaceutical composition is cell-free. 
     
     
         47 . The method of  claim 39 , wherein the brain cancer is glioblastoma. 
     
     
         48 . The method of  claim 39 , wherein the subject has failed prior therapy with temozolomide, radiation therapy, and surgery. 
     
     
         49 . The method of  claim 39 , further comprising administering bevacizumab to the subject. 
     
     
         50 . The method of  claim 39 , wherein the pharmaceutical composition comprises 250 to 400 μg of the IL-13Rα2 peptide and 250 to 400 μg of the EphA2 peptide. 
     
     
         51 . The method of  claim 39 , wherein one or more of the peptides are loaded on dendritic cells.